Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Alvaro Haroun-Izquierdo,Marianna Vincenti,Herman Netskar,Hanna van Ooijen,Bin Zhang,Laura Bendzick,Minoru Kanaya,Pouria Momayyezi,Shuo Li,Merete Thune Wiiger,Hanna Julie Hoel,Silje Zandstra Krokeide,Veronika Kremer,Geir Tjonnfjord,Stéphanie Berggren,Kristina Wikström,Pontus Blomberg,Evren Alici,Martin Felices,Björn Önfelt,Petter Höglund,Bahram Valamehr,Hans-Gustaf Ljunggren,Andreas Björklund,Quirin Hammer,Lise Kveberg,Frank Cichocki,Jeffrey S Miller,Karl-Johan Malmberg,Ebba Sohlberg
DOI: https://doi.org/10.1136/jitc-2022-005577
Abstract:Background: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)+NKG2C+ adaptive NK cells to maximize missing-self reactivity. Methods: We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. Results: ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45dim blast subtypes. Conclusions: These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability.